HCC1569 Cells

HCC1569 is a human breast cancer cell line derived from a primary ductal carcinoma. It exhibits a basal-like phenotype and is characterized as estrogen receptor (ER)-negative and HER2-positive, a molecular subtype with distinct clinical and therapeutic implications. Like other basal-like breast cancers, HCC1569 lacks expression of ER and progesterone receptor (PR), but it displays amplification and overexpression of the ERBB2 (HER2) oncogene, a key target for HER2-directed therapies. The cell line demonstrates a high degree of aneuploidy and harbors multiple genomic alterations relevant to breast cancer biology.

HCC1569 is included in large-scale genomic profiling efforts such as the Cancer Cell Line Encyclopedia (CCLE) and related studies that integrate mutational, copy number, methylation, and expression data. These datasets have shown that HCC1569 carries structural variants and copy number amplifications consistent with aggressive breast tumors, including those involving HER2. Functional genomic screens have highlighted the dependency of this cell line on HER2 signaling pathways, supporting its use in evaluating HER2-targeted therapies and resistance mechanisms.

Additionally, HCC1569 has been characterized for its HLA genotype and expression profile, which has implications for immunotherapy development. It is included in catalogs of HLA typing and neoantigen prediction, offering opportunities for exploring T cell epitope presentation and immune recognition in HER2-positive breast cancer contexts. This immunogenomic annotation makes HCC1569 a valuable resource not only for studying oncogenic signaling but also for evaluating tumor-immune interactions and designing personalized immunotherapies.